S-1: Profusa Registers Shares for Resale, Adopts Bitcoin Treasury Strategy

Profusa, Inc. filed an S-1 registration statement for the resale of up to 42.6 million common shares, including those tied to a $100 million committed equity facility with Ascent Partners, and revealed a new treasury strategy to invest proceeds in Bitcoin.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination on July 11, 2025, with Profusa, Inc. (California corporation) becoming a wholly-owned subsidiary.
• The company is registering 42,594,048 shares of common stock for resale by selling stockholders, including 42,211,548 shares potentially sold to Ascent Partners Fund LLC under a $100 million committed equity facility (CEF).
• Proceeds from the CEF, if any, will be primarily used to purchase Bitcoin, provided the company's cash balance exceeds $5 million; otherwise, funds will first bring the balance to $5 million.
• Profusa is a clinical-stage digital health and medical technology company developing biointegrated sensors, including the Lumee Oxygen Platform (CE Mark in EU, US pivotal study ongoing) and Lumee Glucose Platform (R&D, clinical trials).
• The company reported a net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• As of June 30, 2025, Profusa had a working capital deficit of approximately $63.2 million and cash of $0.1 million.
• The company has substantial doubt about its ability to continue as a going concern, despite recent financing from the business combination and a PIPE investment.
• Milestone Earnout Rights for former Profusa security holders include targets for share price ($12.50 and $14.50), APAC Joint Venture closing with $6 million funding by December 31, 2025, and $11,864,000 in revenue for fiscal year 2026.
• Profusa currently holds $1.0 million in Bitcoin, representing 8.53 Bitcoins, as part of its treasury strategy.
• The company's common stock is listed on the Nasdaq Global Market under the symbol PFSA, with a last sale price of $0.33 per share on October 7, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses and substantial doubt about its ability to continue as a going concern. While it has promising technology and a new funding facility, the highly speculative Bitcoin treasury strategy and ongoing need for regulatory approvals introduce considerable risk. The current stock price is very low, and significant dilution is expected.

Positives

• The company successfully completed its business combination with NorthView Acquisition Corporation on July 11, 2025, becoming a public entity.
• Profusa has secured a committed equity facility of up to $100 million with Ascent Partners Fund LLC, providing a potential source of future funding.
• The Lumee Oxygen Platform has received CE Mark approval in the European Union, indicating regulatory validation for commercialization in that region.
• The Lumee Glucose Platform has shown promising proof-of-concept clinical data with a mean absolute relative difference (MARD) of approximately 11% and up to nine months of functionality post-injection, with zero device-related serious adverse events.
• Profusa has a robust intellectual property portfolio with 20 issued U.S. patents and 80 rest-of-world patents, expiring between 2030 and 2040.
• The company has a dual commercialization strategy for Lumee Glucose, targeting both direct-to-hospital and direct-to-pharmacy sales, aiming to maximize user base and flexibility.

Negatives

• The company has incurred significant net operating losses since inception, with a net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• There is substantial doubt about Profusa's ability to continue as a going concern, despite recent financing, indicating ongoing financial instability.
• The company has a significant working capital deficit of approximately $63.2 million as of June 30, 2025.
• Cash and cash equivalents were very low at $0.1 million as of June 30, 2025.
• The PPP Loan 2 of $1.383 million is in default due to non-payment, and the company is incurring a default interest rate of 24% per annum on the Tasly Convertible Debt.
• The company will not receive any proceeds from the resale of shares by selling stockholders, only from its direct sales to Ascent under the CEF.
• The Bitcoin treasury strategy exposes the company to extreme price volatility, which could significantly impact financial results and stock price.
• The company's common stock traded at $0.33 per share on October 7, 2025, significantly below the $10.00 per share assumed value for the business combination and the $12.00/$18.00 warrant redemption triggers, indicating poor market performance.
• The issuance of shares under the CEF will cause dilution to existing stockholders, and the perception of such sales could further depress the stock price.
• Commercialization of Lumee Oxygen in the U.S. and Lumee Glucose in any jurisdiction is dependent on obtaining regulatory approvals, which cannot be assured and may be delayed.

Risks

• Inability to predict the actual number of shares sold under the Purchase Agreement or the gross proceeds from those sales.
• Dilution to existing stockholders from the sale and issuance of common stock to Ascent, and potential stock price decline due to actual or perceived sales.
• Investors buying Purchase Shares from Ascent at different times may pay different prices and experience varying levels of dilution.
• Proceeds from sales of common stock under the Purchase Agreement will be primarily used to purchase Bitcoin, which is a highly volatile asset.
• Substantial doubt about the ability to continue as a going concern, which may hinder obtaining further financing.
• Limited operating history and a history of incurring significant losses since inception, with anticipated continued losses for several years.
• Operating in a highly competitive market with large, well-established companies possessing significant resources.
• Risks associated with international operations, including local product preferences, longer payment cycles, foreign currency fluctuations, less intellectual property protection, trade protection measures, and political/economic instability.
• Consumer confusion about product features and technology of oxygen monitoring and CGM products could lead to competitive product purchases or conflation of adverse events.
• High reliance on Lumee Oxygen Platform for commercial revenue until additional products receive regulatory approval.
• Dependence on third-party suppliers and outsourcing, making the company vulnerable to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• No guarantee of FDA 510(k) clearance or PMA approval for products, which would adversely affect business growth.
• Inability to successfully complete pre-clinical studies or clinical trials necessary for regulatory applications, impairing commercialization of CGM systems.
• Products may cause or contribute to adverse medical events or be subject to failures/malfunctions requiring FDA reporting, leading to sanctions or reputational harm.
• Discovery of serious safety issues or product recalls could have a negative impact.
• Quality problems could lead to recalls, safety alerts, and reputational harm.
• Changes to the regulatory landscape may impact the ability to obtain marketing authorization for future product developments.
• Failure to comply with laws, regulations, and contract requirements relating to healthcare reimbursement may subject the company to penalties.
• Subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security, which could result in claims, penalties, and increased costs.
• Cybersecurity risks and cyber incidents could compromise confidential data or critical systems, leading to harm to customers, expenses, liability, and reputational damage.
• Potential claims of infringement or misappropriation of intellectual property rights of others, leading to shipping prohibitions, licensing requirements, or monetary damages.
• Involvement in lawsuits to protect or enforce patents, which could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights globally, allowing competitors to produce products based on technology.
• Inability to protect the confidentiality of trade secrets, diminishing technology value.
• Need or choice to obtain licenses from third parties, with no assurance of obtaining them on acceptable terms.
• Compliance with procedural requirements for patent protection, with non-compliance potentially reducing or eliminating patent rights.
• Inadequate patent terms to protect competitive position for an adequate amount of time.
• Potential claims challenging inventorship or ownership of patents and other intellectual property.
• Intellectual property rights may not address all potential threats, limiting competitive advantage.
• Inability to successfully maintain effective internal control over financial reporting, impacting investor confidence and stock price.
• Environmental, social, and corporate governance (ESG) regulations may complicate the supply chain and affect customer relationships.
• Uncertainty in domestic and global economic and political conditions, making product demand difficult to predict.
• Changes in financial accounting standards or practices or existing taxation rules may cause unexpected revenue/expense fluctuations.
• Identified material weaknesses in internal control over financial reporting, potentially affecting accurate and timely financial statements.
• Climate change may have a long-term impact on business operations and supply chain.
• Risk of product liability claims, leading to damages, fines, penalties, and injunctions.
• Increased costs and additional regulations as a public company.
• Bitcoin treasury strategy exposes the company to counterparty risks, including custodian insolvency.
• Regulatory change reclassifying Bitcoin as a security could lead to classification as an investment company under the 1940 Act, adversely affecting Bitcoin price and stock price.
• Temporary or permanent blockchain forks to Bitcoin could adversely affect the business.
• Due diligence procedures to mitigate transaction risk with sanctioned entities may fail.
• No assurance of compliance with Nasdaq continued listing standards, potentially leading to delisting.
• Future sales, or the perception of future sales, by shareholders could cause the market price to decline.
• Grant and future exercise of registration rights may adversely affect the market price.
• No current plans to pay cash dividends, meaning investors may only receive a return by selling shares at a higher price.
• Issuance of additional shares or equity securities without stockholder approval could dilute ownership interests and depress stock price.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• Potential for securities litigation, which is expensive and diverts management attention.

Future Outlook

Profusa expects to continue incurring significant losses for several years as it commercializes existing products and develops new ones. The company plans to launch Lumee Oxygen in Europe in early 2026 and aims for US FDA marketing authorization by late 2026. Lumee Glucose is targeted for EU launch in 2025 and US launch in late 2026 or early 2027. Future growth is anticipated through expanding its product portfolio to other analytes and partnering with telemedicine and health and wellness coaching sectors by providing real-time biochemistry data streams.

Management Comments

• Management believes the Lumee Glucose platform's ability to provide continuous glucose monitoring with a single initial injection is an attractive alternative for diabetes management.
• Management believes the liquidity from the business combination and PIPE convertible note has mitigated but not fully alleviated the substantial doubt about the company's ability to continue as a going concern.
• Management believes that the combination of the potential advantages of its platform will enable it to generate both short-term revenue in high-value clinical applications and leverage core technology to develop products for other chronic conditions.
• Management believes its validated core technology can easily bridge the gap in the current technology landscape for monitoring real-time biochemistry.
• Management believes that its solution could benefit those in the type 2 and pre-diabetes populations to both potentially broaden the product reach beyond currently available solutions, and generate a broad set of clinical data.

Industry Context

The medical device market, particularly for glucose and oxygen monitoring, is highly competitive and characterized by rapid technological change. Profusa's biointegrated sensor technology aims to differentiate itself by offering long-term, continuous monitoring with a user-friendly form factor and lower cost compared to existing solutions. The industry is seeing a trend towards technology-enabled healthcare, telemedicine, and remote patient monitoring, which Profusa aims to leverage by providing critical real-time biomarker data. However, it faces competition from large, established players like Abbott, Medtronic, and Roche, who have significant resources and established market presence. The broader digital assets industry, including Bitcoin, is subject to significant legal, commercial, regulatory, and technical uncertainty, which adds a layer of risk to Profusa's treasury strategy.

Comparison to Industry Standards

• Lumee Glucose aims to provide continuous glucose monitoring with a single initial injection, offering an attractive alternative to frequent finger sticks (standard glucometers) or weekly sensor replacements (current short-term needle-type CGMs like Dexcom G6, Abbott Freestyle Libre 2, Medtronic Guardian Connect).
• Profusa's hydrogel sensor is designed to overcome the foreign body response, allowing for longer functionality (up to 6-9 months) compared to current CGMs typically limited to 7-14 days, and a less invasive deployment than surgically implanted 12-month solutions like Senseonics Eversense E3.
• The Lumee Oxygen Platform competes with devices using transcutaneous oximetry (TCPO2) from companies like Perimed AB, Radiometer Medical, or SenTec AG, and doppler/cuff devices measuring Ankle-Brachial Index (ABI), Toe-Brachial Index (TBI), or Segmental Pressure Values (SPP).
• Profusa believes its technology offers a lower cost and broader accessibility for a wider user base (type 2 and pre-diabetes populations) compared to current CGM solutions, which are often limited by high costs and insurance reimbursement to brittle type 1 and 2 patients.
• The company's approach of decoupling the sensor and reader elements is believed to offer advantages in system cost and reusability of the more expensive reader component, unlike integrated systems from competitors.

Management Changes

Corporate Governance

Legal Proceedings

• Currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million accrued.
• The company is subject to various claims, complaints, and legal actions arising out of the ordinary course of business, including commercial insurance, product liability, or employment-related matters.

Related Party Transactions

• Profusa entered into a Binding Term Sheet for APAC Joint Venture with Tasly (International) Healthcare Capital Company Limited, a related party, for commercialization of Lumee Glucose and Lumee Oxygen in the Asia Pacific region.
• Profusa has a short-term loan agreement (Tasly Convertible Debt) with Tasly (International) Healthcare Investment & Development Company Limited, a shareholder, with $2.5 million outstanding as of June 30, 2025, and is currently in default.
• Profusa has issued promissory notes to its founders and insiders, with an aggregate outstanding amount of approximately $940,000 as of June 30, 2025, some of which are past due or payable on demand.
• NorthView Sponsor I, LLC, an affiliate of officers and directors, purchased founder shares and private placement warrants, and previously received administrative service fees.
• NorthView Sponsor I, LLC provided a Convertible Working Capital Promissory Note to NorthView, with $1,919,796 principal outstanding as of June 30, 2025, convertible into common stock at $2.22 per share.

Stakeholder Impact

• Existing shareholders will experience significant dilution from the issuance of common stock under the Committed Equity Facility and other equity issuances.
• The company's financial instability and 'going concern' doubt pose a high risk to investors, potentially leading to loss of investment.
• Employees and management face challenges related to the company's financial health and the need to attract and retain skilled personnel in a competitive industry.
• Customers may be impacted by potential delays in product commercialization and regulatory approvals, as well as any product recalls or safety issues.
• Suppliers and creditors face risks due to the company's financial condition, including potential delays or defaults on payments, as evidenced by the defaulted PPP loan and Tasly Convertible Debt.
• The Bitcoin treasury strategy introduces additional volatility and counterparty risks for all stakeholders, as the value of the company's assets could fluctuate dramatically.

Next Steps

• Initiate commercialization efforts for Lumee Oxygen in Europe in early 2026.
• Continue the US pivotal study for Lumee Oxygen for submission for US FDA marketing authorization, targeting late 2026.
• Target Lumee Glucose launch in the European Union in 2025, subject to regulatory approval.
• Start the next validation study for Lumee Glucose in the first half of 2026 and regulatory submission in early 2026.
• Target Lumee Glucose US FDA marketing authorization in late 2026 or early 2027.
• Continue discussions with potential partners in Asia for the APAC Joint Venture, with definitive agreements in final agreed form.
• Potentially develop sensors for other analytes (lactate, CO2, ethanol, pH) to expand the product portfolio.
• Strategically engage in commercial B2B relationships to capture portions of the coaching, telemedicine, and health and wellness segments.
• Remediate identified material weaknesses in internal control over financial reporting by establishing reporting controls consistent with a public company of this size.

Key Dates

Recommendation

Profusa faces severe financial distress, evidenced by recurring significant net losses, a substantial working capital deficit, and explicit 'substantial doubt about its ability to continue as a going concern.' While the company has secured a committed equity facility, the proceeds are earmarked for a highly volatile Bitcoin treasury strategy, which introduces extreme and unpredictable risk to its asset base and earnings. The current stock price is very low, and the impending dilution from the committed equity facility and other conversions will further erode shareholder value. The company's core medical device products are still in early commercialization or clinical trial phases, with no guarantee of timely regulatory approval or market acceptance, and face intense competition. Given the profound financial instability, speculative treasury strategy, and uncertain path to profitability, the stock represents an exceptionally high-risk investment with a strong likelihood of further capital impairment.

Keywords

Biointegrated Sensors, Continuous Glucose Monitoring, Tissue Oxygen Monitoring, Lumee Oxygen Platform, Lumee Glucose Platform, SEC Filing, S-1 Registration, Committed Equity Facility, Bitcoin Treasury Strategy, Medical Technology, Digital Health, Risk Factors, Dilution, Going Concern, Clinical Trials, FDA Approval, CE Mark, Corporate Governance, Nasdaq Listing, Ascent Partners, PIPE Investment, Healthcare Innovation